Control of a Candida glabrata prosthetic endovascular infection with posaconazole

被引:17
作者
Anstead, G. M.
Martinez, M.
Graybill, J. R.
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA
[2] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Med Ctr, Med Serv, San Antonio, TX USA
[3] David Powell Clin, Austin, TX USA
关键词
Candida glabrata; infection; posaconazole; transjugular intrahepatic portosystemic shunt;
D O I
10.1080/13693780500049152
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A 63-year-old man with a history of cirrhosis of the liver developed Candida glabrata fungemia after undergoing transjugular intrahepatic portosystemic shunt ( TIPS) placement. Treatment with oral fluconazole was initially effective, but when the patient became neutropenic, subsequent blood cultures grew C. glabrata and a thrombus developed, which partially occluded the stent. Despite treatment with fluconazole, blood cultures remained positive for C. glabrata. Treatment with posaconazole resulted in clinical improvement and the patient had only intermittently positive fungal cultures for 6 weeks. A CT scan showed resolution of the inferior vena cava thrombus. Subsequently, the patient developed hepatocellular carcinoma and hepatic encephalopathy and became noncompliant with posaconazole. Blood cultures again became positive for C. glabrata. The patient died a few weeks after the diagnosis of hepatocellular carcinoma, but the cause of death was believed to be worsening liver dysfunction, not C. glabrata infection. Posaconazole had controlled the infection for about 3 months prior to his death. In conclusion, posaconazole may be a useful option in the management of prosthetic endovascular infections caused by C. glabrata.
引用
收藏
页码:273 / 277
页数:5
相关论文
共 30 条
[1]  
[Anonymous], 1998, M38P NCCLS
[2]   Infection of transjugular intrahepatic portosystemic shunt devices: Three cases and a review of the literature [J].
Armstrong, PK ;
MacLeod, C .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) :407-412
[3]   In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata [J].
Barchiesi, F ;
Spreghini, E ;
Maracci, M ;
Fothergill, AW ;
Baldassarri, I ;
Rinaldi, MG ;
Scalise, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) :3317-3322
[4]  
Brown RS, 1998, AM J GASTROENTEROL, V93, P636, DOI 10.1111/j.1572-0241.1998.180_b.x
[5]   Flucytosine primary resistance in Candida species and Cryptococcus neoformans [J].
Cuenca-Estrella M. ;
Díaz-Guerra T.M. ;
Mellado E. ;
Rodríguez-Tudela J.L. .
European Journal of Clinical Microbiology and Infectious Diseases, 2001, 20 (4) :276-279
[6]   Torulopsis glabrata fungemia as a complication of a clotted transjugular intrahepatic portosystemic shunt [J].
Darwin, P ;
Mergner, W ;
Thuluvath, P .
LIVER TRANSPLANTATION AND SURGERY, 1998, 4 (01) :89-90
[7]   Risk factors and prevention of early infection after implantation or revision of transjugular intrahepatic portosystemic shunts -: Results of a randomized study [J].
Deibert, P ;
Schwarz, S ;
Olschewski, M ;
Siegerstetter, V ;
Blum, HE ;
Rössle, M .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (08) :1708-1713
[8]   Sustained bacteremia associated with transjugular intrahepatic portosystemic shunt (TIPS) [J].
DeSimone, JA ;
Beavis, KG ;
Eschelman, DJ ;
Henning, KJ .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (02) :384-386
[9]   In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei [J].
Drago, M ;
Scaltrito, MM ;
Morace, G .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (08) :619-624
[10]   A case of infective endotipsitis [J].
Eversman, D ;
Chalasani, N .
GASTROENTEROLOGY, 1999, 117 (02) :514-514